Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Neurocrine Biosciences reports strong Q4 performance and eyes growth

Neurocrine Biosciences delivered strong performance in Q4 2022, with robust INGREZZA sales and a positive outlook for 2023, supported by significant investments in SG&A and R&D.
The company's focus on expanding into long-term care, advancing pipeline assets, and collaborations for innovative treatments positions it well for growth and addressing unmet needs.
While facing challenges in managing increased spending and market dynamics, Neurocrine remains optimistic about opportunities in expanding treatment reach, market penetration, and advancing clinical programs.

Neurocrine Biosciences reports strong Q1 performance and eyes international expansion

Neurocrine Biosciences had a strong Q1 performance with record sales, upcoming milestones, and disciplined expense management.
The company faces challenges in certain therapeutic categories but is optimistic about addressing unmet needs and expanding internationally.
Opportunities lie in innovative science, market positioning, and portfolio expansion, positioning Neurocrine for future growth.
Addressing concerns around drug interactions, dosing strategies, and trial risks will be crucial for maintaining clinical success and patient safety.

Neurocrine Biosciences excels in Q2, eyes growth opportunities ahead

Neurocrine Biosciences shows strong financial performance and growth prospects.
Focus on INGREZZA's persistency and pipeline advancements drives optimism.
Challenges include market dynamics and clinical trial complexities.
Opportunities lie in new indications, long-term care expansion, and telemedicine.

Neurocrine Biosciences excels in Q3, eyes growth in LTC segment

Neurocrine Biosciences delivered a strong Q3 performance with robust sales, positive regulatory developments, and promising pipeline advancements.
The company's focus on expanding indications, exploring combination therapies, and addressing market opportunities positions it for future growth.
While facing challenges in market evaluation and competition, Neurocrine Biosciences has opportunities to leverage its strengths and drive innovation.
Investors can look forward to upcoming events like the Analyst Day and R&D Day for deeper insights into the company's strategic direction and growth potential.

Neurocrine Biosciences excels in 2023, eyes Crinecerfont launch success

Neurocrine Biosciences had a strong 2023 with notable achievements in sales growth and pipeline advancements. While facing challenges in market dynamics and pricing negotiations, the company is well-positioned to leverage opportunities in upcoming launches and strategic growth initiatives.

Neurocrine Biosciences excels in Q1 with strong sales and pipeline advancements

Neurocrine Biosciences delivered a strong performance in Q1 2024, driven by robust INGREZZA sales, promising Phase II results for NBI-845, and advancements in Crinecerfont development.
The company's strengths lie in its diverse pipeline, financial stability, and strategic focus on chronic therapy and tolerability, positioning it for future growth and innovation.
While facing challenges in dosing optimization and revenue management, Neurocrine has opportunities to leverage its pipeline, explore new treatments, and differentiate its offerings in the market.

Neurocrine Biosciences excels in Q3, poised for growth ahead

Neurocrine Biosciences showcased robust performance in Q3, with strong INGREZZA sales and pipeline success, positioning for future growth.
The company's strengths lie in its expanded sales team, leadership quality, and commitment to innovation and value creation for shareholders.
Challenges include potential payer reimbursement issues, FDA interactions for Phase III strategy, and competitive pressures in the market.
Opportunities abound with upcoming regulatory approvals, pipeline advancements, and targeted commercial strategies for new product launches.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Takeda Pharmaceutical

During a May 6 earnings conference call, the head of business development and strategy for Neurocrine Biosciences Inc (NASDAQ:NBIX) said the company was looking for other partnerships, similar to those it had recently struck with Xenon Pharmaceuticals Inc.

Neurocrine Adds to Pipeline With $2 Billion Takeda Deal

ACADIA Pharma

Biogen

BioXcel Therapeutics

Cortexyme Inc

Intra-Cellular Therapies

SAGE Therapeutics

Zynerba Pharmaceuticals

The 2020 year is practically halfway done, and this has really been the year of the biotech.

Canaccord Genuity’s Top Biopharma Catalysts for the Rest of 2020

Neurocrine's full Phase II data presentation on crinecerfont in adult patients with CAH didn't have many surprises, but the positive efficacy and safety data were welcome.

Full Phase II Data Reinforces Crinecerfont As A Serious Opportunity For Neurocrine Biosciences

SAN DIEGO, June 8, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive data from its completed open-label, multiple-dose, dose-finding, Phase II clinical study of crinecerfont (NBI-74788), demonstrating meaningful reductions in all three key disease...

Neurocrine Biosciences Reports Positive Phase II Data for Crinecerfont in Adults with Congenital Adrenal Hyperplasia at ENDO Online 2020

Biotech company Neurocrine Biosciences is expected to deliver an update on a rare-disease program next week — offering a potential catalyst for NBIX stock, an analyst said Thursday.
The post Here's The Next Catalyst For Buy Zone-Lingering Neurocrine Biosciences appeared first on Investor's Business Daily.

Here's The Next Catalyst For Buy Zone-Lingering Neurocrine Biosciences

SAN DIEGO, May 26, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Jefferies Virtual Healthcare Conference at 11:00 a.m. ET on Tuesday, June 2, 2020. Kevin Gorman, Chief Executive Officer, will present at the conference. The live presentation will be...

Neurocrine Biosciences to Present at the Jefferies Virtual Healthcare Conference

Bristol-Myers

QuidelOrtho Corp

Teladoc

Tandem Diabetes Care

Several top health care stocks are in buy zones or setting up, including Teladoc and Neurocrine Biosciences. They are all worth adding to your watchlist.

Teladoc, Bristol Myers, Quidel, Neurocrine Bio, Tandem Diabetes: 5 Health Stocks To Monitor Closely

SAN DIEGO, May 14, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the RBC Capital Markets 2020 Global Healthcare Conference at 3:40 p.m. ET on Tuesday, May 19, 2020. Kevin Gorman, Chief Executive Officer, will present at the conference. The live...

Neurocrine Biosciences to Present at the RBC Capital Markets 2020 Global Healthcare Conference

The biopharmaceutical company has seen shares rise 44.5% in less than two months.

Is Now a Good Time To Buy Neurocrine Biosciences?

Activision Blizzard

GoDaddy

HubSpot

RingCentral

Increasingly, top companies that we cover on Wall Street are starting to agree that the volatility the stock market is encountering now, along with the beating the economy is taking, should fade in the second half of 2020.

Red-Hot Tech and Biotech Companies Highlight Jefferies Top Stocks to Buy

The company's Ingrezza continues to power its revenue and profitability growth.

Neurocrine Biosciences Q1 Beats on Earnings, Revenue

Ingrezza sales exceeded Street expectations, and management's pre-Covid-19 efforts in telemedicine may help reduce the outbreak's impact on prescription growth and patient compliance.

Neurocrine Biosciences Still Making Smart Moves To Build Long-Term Value

Neurocrine Bioscineces' (NBIX) CEO Kevin Gorman on Q1 2020 Results - Earnings Call Transcript

Neurocrine (NBIX) delivered earnings and revenue surprises of 46.43% and 8.30%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences (NBIX) Q1 Earnings and Revenues Top Estimates

Neurocrine Biosciences: A Quality Biopharma To Consider On Any Pullbacks

Neurocrine Biosciences (NBIX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Neurocrine Biosciences (NBIX) This Earnings Season?

The company's second commercial drug will launch later this year.

FDA Approves Neurocrine Biosciences' Parkinson's Drug

Shares of Neurocrine Biosciences Inc. NBIX, +2.88% gained 2.8% in trading on Monday after the company said the Food and Drug Administration had approved its Parkinson's disease drug Ongentys.

Neurocrine's stock is up on FDA approval of Parkinson's drug

CRISPR Therapeutics

Gilead Sciences

Galapagos

Incyte

Regeneron Pharmaceuticals

Acceleron Pharma

Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.

7 Beautiful Biotech Stocks to Buy Here

Collegium Pharmaceutical

COLL vs. NBIX: Which Stock Is the Better Value Option?

COLL or NBIX: Which Is the Better Value Stock Right Now?

Neurocrine Biosciences shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
The post Stock Upgrades: Neurocrine Biosciences Shows Rising Relative Strength appeared first on Investor's Business Daily.

Stock Upgrades: Neurocrine Biosciences Shows Rising Relative Strength

The IBD SmartSelect Composite Rating for Neurocrine Biosciences increased from 92 to 96 Thursday. 
The post Neurocrine Biosciences Stock Rating Jumps Amid Expanded Use Plans appeared first on Investor's Business Daily.

Neurocrine Biosciences Stock Rating Jumps Amid Expanded Use Plans

Neurocrine Biosciences saw its IBD SmartSelect Composite Rating jump to 96 Wednesday, up from 94 the day before. 
The post Neurocrine Biosciences Earns Membership In 95-Plus Composite Rating Club appeared first on Investor's Business Daily.

Neurocrine Biosciences Earns Membership In 95-Plus Composite Rating Club

The biotech trounced Wall Street revenue and earnings estimates thanks to strong sales for its tardive dyskinesia drug.

How Neurocrine Biosciences Crushed It in Q4

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q4 2019 Results - Earnings Call Transcript

News for Neurocrine Biosciences Stock (NBIX)